Drug intelligence / Profile preview

vectorized HER2 antibody

Development stage: Preclinical
Lead developer: Voyager Therapeutics
Modality: Antibody-Based Therapeutics, Gene Therapies
Administration: Intravenous

Overview

The vectorized HER2 antibody is an experimental gene therapy developed by Voyager Therapeutics for the treatment of HER2-positive (HER2+) brain metastases, particularly those originating from breast cancer. This biologic therapy utilizes an adeno-associated virus (AAV) vector, specifically the proprietary TRACER capsid VCAP-102 (a variant of AAV9), to deliver genetic material encoding an anti-HER2 monoclonal antibody. By transducing cells within the central nervous system, the therapy enables the brain to produce therapeutic antibodies locally, thereby overcoming the blood-brain barrier limitations that hinder conventional systemic therapies like trastuzumab. The expressed antibody binds to the Human Epidermal Growth Factor Receptor 2 (HER2), inhibiting tumor cell proliferation and mediating antibody-dependent cell cytotoxicity (ADCC).

Other names: AAV-delivered anti-HER2 antibodyVCAP-102 vectorized HER2 antibodyVCAP102 vectorized HER2 antibodyVCAP 102 vectorized HER2 antibody

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on vectorized HER2 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vectorized HER2 antibody.

Explore the full profile